Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pharmacology, Biochemistry and Behavior

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pbb.2010.05.029PMID 20570692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of Thermogenesis in Antipsychotic Drug‐induced Weight Gain

  2009influential reference
• Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats.

  2009cited by this paper
• Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine

  2009cited by this paper
• Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats

  2009cited by this paper
• Olanzapine plus 17-beta estradiol produce antidepressant-like actions in rats forced to swim.

  2009cited by this paper
• Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis

  2009cited by this paper
• Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A.

  2008cited by this paper
• Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.

  2008cited by this paper
• Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm.

  2008cited by this paper
• Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities

  2007cited by this paper
• Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.

  2007cited by this paper
• Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.

  2006cited by this paper
• Second-Generation Antipsychotics

  2006cited by this paper
• A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Eating Behaviors

  2005cited by this paper
• Hydroxycitric acid delays intestinal glucose absorption in rats.

  2005cited by this paper
• A parametric analysis of olanzapine-induced weight gain in female rats

  2005influential reference
• Gait disturbances in patients with schizophrenia and adaptation to treadmill walking

  2005cited by this paper
• Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain.

  2005cited by this paper
• Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?

  2005cited by this paper
• Adolescent Weight Loss During Treatment with Olanzapine

  2004cited by this paper
• Obesity, Diabetes, and the Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy

  2003cited by this paper
• The Atypical Antipsychotics Risperidone, Clozapine and Olanzapine Differ Regarding Their Sedative Potency in Rats

  2003cited by this paper
• Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.

  2003cited by this paper
• Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex

  2003cited by this paper
• Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy

  2003influential reference
• Atypical Antipsychotic Drug Use and Diabetes

  2002cited by this paper
• Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol.

  2002cited by this paper
• Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.

  2002cited by this paper
• Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.

  2002cited by this paper
• Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

  2001cited by this paper
• Association of olanzapine-induced weight gain with an increase in body fat.

  2001cited by this paper
• 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.

  2000cited by this paper
• Pharmacology of flavor preference conditioning in sham-feeding rats: effects of dopamine receptor antagonists.

  2000cited by this paper
• Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.

  2000influential reference
• Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro

  1999cited by this paper
• Serotonin (5-Hydroxytryptamine), a Novel Regulator of Glucose Transport in Rat Skeletal Muscle*

  1999cited by this paper
• Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.

  1999cited by this paper
• Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum

  1998cited by this paper
• Olanzapine: Interaction Study with Imipramine

  1997cited by this paper
• Localization of α2A- and α2B-Adrenergic Receptor Subtypes in Brain

  1996cited by this paper
• Effects of Olanzapine on Regional C-Fos Expression in Rat Forebrain

  1996cited by this paper
• Changes in daily rhythms of body temperature and activity after a single social defeat in rats.

  1996influential reference
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

  1996cited by this paper
• Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain.

  1996cited by this paper
• Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay.

  1995cited by this paper
• Autoradiographic mapping of M3 muscarinic receptors in the rat brain.

  1993cited by this paper
• Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

  1988cited by this paper
• The distribution and cells of origin of serotonergic inputs to the paraventricular and supraoptic nuclei of the rat.

  1983cited by this paper

• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice

  2025cites this paper
• Aprepitant boasted a protective effect against olanzapine-induced metabolic syndrome and its subsequent hepatic, renal, and ovarian dysfunction; Role of IGF1/p-AKT/FOXO1 and NFκB/IL-1β/TNF-α signaling pathways in female Wistar albino rats.

  2024cites this paper
• Is Dosage Adjustment for Olanzapine Really Necessary?

  2023cites this paper
• Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.

  2023cites this paper
• Olanzapine-Induced Therapeutic Hypothermia Attenuates Renal Injury in Rats after Asphyxial Cardiac Arrest and Resuscitation

  2022cites this paper
• Chronic Agmatine Treatment Prevents Olanzapine-induced Obesity and Metabolic Dysregulation in Female Rats.

  2022cites this paper
• Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats

  2021cites this paper
• High fat worsens olanzapine induced metabolic abnormalities in rats

  2020cites this paper
• Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation

  2020cites this paper
• Modeling of antipsychotics-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.

  2019cites this paper
• The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors

  2019cites this paper
• SEX DIFFERENCES IN THE BEHAVIOURAL RESPONSES TO OLANZAPINE IN RATS A thesis submitted in partial fulfilment of the Requirements for the Degree of Master of Science in Psychology By

  2018influential citation
• Soluble dietary fiber fraction of Trigonella foenum graecum seeds prevent olanzapine induced metabolic syndrome in rats

  2018cites this paper
• Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia

  2018cites this paper
• Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats.

  2017cites this paper
• Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression

  2017influential citation
• A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.

  2016cites this paper
• Atypical antipsychotics and effects on feeding: from mice to men

  2016cites this paper
• Olanzapine disturbs luminal glucose absorption via inhibition of gastrointestinal motility

  2015cites this paper
• Olanzapine inhibits body weight gain in male Wistar rats, which is amplified by adjunctive Topiramate treatment; hepatic proteome analysis points towards a disruption in growth hormone regulation

  2015cites this paper
• Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways.

  2015cites this paper
• Gewichtszunahme unter Therapie mit Antipsychotika: Was wissen wir und was können wir tun?

  2015cites this paper
• The atypical effects of olanzapine on body weight regulation

  2015cites this paper
• Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats.

  2014cites this paper
• Oxytocin: the neurochemical mediator of social life

  2014cites this paper
• Modelling olanzapine-induced weight gain in rats.

  2014influential citation
• Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma.

  2014cites this paper
• A preclinical evaluation of antipsychotic drug-induced metabolic side-effects : a focus on glucose dysregulation and insulin resistance

  2013cites this paper
• Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects

  2013cites this paper
• Technical issues concerning peripheral and central administration of Olanzapine in rats

  2013cites this paper
• The role of hypothalamic pathways in the metabolic side effects of Olanzapine

  2013cites this paper
• Chronic treatment with Olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects

  2013cites this paper
• The role of ghrelin signalling in second-generation antipsychotic-induced weight gain.

  2013cites this paper
• The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature

  2012cites this paper
• Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.

  2012cites this paper
• Antipsychotica geïnduceerd overgewicht en insulineresistentie

  2012cites this paper
• Residual dopamine receptor desensitization following either high- or low-dose sub-chronic prior exposure to the atypical anti-psychotic drug olanzapine

  2012cites this paper
• Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.

  2012cites this paper